<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00707850</url>
  </required_header>
  <id_info>
    <org_study_id>BRCGL-08-06</org_study_id>
    <nct_id>NCT00707850</nct_id>
  </id_info>
  <brief_title>Pegasys® Plus Ribavirin in Thalassemic Patients With Hepatitis C Virus Infection</brief_title>
  <official_title>A Study on PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin) in Iranian Thalassemic Patients With Chronic Hepatitis C Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baqiyatallah Medical Sciences University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Baqiyatallah Research Center for Gastroenterology and Liver Diseases</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tehran Hepatitis Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guilan University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tabriz Research Center for Gastroenterology and Liver Diseases</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Baqiyatallah Medical Sciences University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Antiviral treatment of HCV in thalassemia has raised concerns of ribavirin-induced hemolysis&#xD;
      and increased iron loading. Blood Transfusion in Thalassemic patients are a known high risk&#xD;
      for acquiring hepatitis C. The investigators are trying the PEGASYS (Peginterferon&#xD;
      alpha-2a(40 KD)) plus Ribavirin in Thalassemic patients with HCV.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with Thalassemia receive chronic blood transfusions and have an increased prevalence&#xD;
      of chronic Hepatitis C virus (HCV) infection, particularly if transfused before HCV&#xD;
      serological testing became available. The investigators enrolled 300 patients into the study.&#xD;
      The patients received PEGASYS (Peginterferon alpha-2a(40 KD)) 180 microgram per week plus&#xD;
      COPEGUS (Ribavirin) 1000 milligram for weight less than or equal 75 kg and 1200 milligram for&#xD;
      more than 75 kg for 48 weeks. Follow up period is 6 months after treatment. The patients are&#xD;
      visited every 4 weeks with biochemistry lab tests. The patients are checked with quantitative&#xD;
      HCV RNA (Ribonucleic Acid) on the third months after initiation of the treatment to assess&#xD;
      early virologic response and at the end of the study for complete response rate and on the&#xD;
      six month after treatment completion for sustained response rate. The patients with&#xD;
      undetectable HCV RNA are considered as responders.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Early Virologic Response</measure>
    <time_frame>After 12 weeks of Treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>End of Treatment Response</measure>
    <time_frame>48 Weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Sustained Virologic Response</measure>
    <time_frame>24 weeks after Treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rapid Virologic Response</measure>
    <time_frame>One month after Treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerability of drugs for whole therapy period</measure>
    <time_frame>During Treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical response (ALT)</measure>
    <time_frame>End of Treatment AND 24 weeks after Treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Parameters</measure>
    <time_frame>During Treatment AND End of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Hepatitis C</condition>
  <condition>Thalassemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Thalassemic Patients with HCV</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin)</intervention_name>
    <description>PEGASYS: 180 microgram per week (Injection) Plus Ribavirin: [=&lt;75 kg: 1000 mg; &gt;75 kg: 1200 mg per day (PO)]</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Peginterferon Alfa-2a (40KD) plus COPEGUS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HCV RNA positive&#xD;
&#xD;
          -  Age older than 12 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Ongoing pregnancy or breast feeding&#xD;
&#xD;
          -  History (Hx) of Hepatocellular Carcinoma (HCC)&#xD;
&#xD;
          -  Hx of alcoholic liver disease&#xD;
&#xD;
          -  Hx of bleeding from esophageal varices&#xD;
&#xD;
          -  Hx of hemochromatosis&#xD;
&#xD;
          -  Hx of autoimmune hepatitis&#xD;
&#xD;
          -  Hx of Suicidal attempt&#xD;
&#xD;
          -  Hx of cerebrovascular dis&#xD;
&#xD;
          -  Hx of severe retinopathy&#xD;
&#xD;
          -  Hx of severe psoriasis&#xD;
&#xD;
          -  Hx of scleroderma&#xD;
&#xD;
          -  Hx of metabolic liver disease&#xD;
&#xD;
          -  Hx of Systemic Lupus Erythematosus (SLE)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seyed-Moayed Alavian, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Baqiyatallah Research Center for Gastroenterology and Liver Disea</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Seyyed Mohammad Miri, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Baqiyatallah Research Center for Gastroenterology and Liver Disea</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pegah Karimi, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baqiyatallah Research Center for Gastroenterology and Liver Diseases</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maryam Keshvari, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Iranian blood Transfusion Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bita Behnava, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baqiyatallah Research Center for Gastroenterology and Liver Diseases</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohammad Hossein Somi, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Research Center for Gastroenterology and Hepatology, Tabriz University of Medical Sciences, Tabriz</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fariborz Mansour-Ghanaei, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gastroenterology and Liver Diseases, Gastrointestinal and Liver Diseases Research Center (GLDRC), Guilan University of Medical Sciences, Rasht, Iran</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Baqiyatallah Research Center for Gastroenterology and Liver Diseases</name>
      <address>
        <city>Tehran</city>
        <zip>14155-3651</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <reference>
    <citation>Harmatz P, Jonas MM, Kwiatkowski JL, Wright EC, Fischer R, Vichinsky E, Giardina PJ, Neufeld EJ, Porter J, Olivieri N; Thalassemia Clinical Research Network. Safety and efficacy of pegylated interferon alpha-2a and ribavirin for the treatment of hepatitis C in patients with thalassemia. Haematologica. 2008 Aug;93(8):1247-51. doi: 10.3324/haematol.12352. Epub 2008 Jun 12.</citation>
    <PMID>18556414</PMID>
  </reference>
  <verification_date>September 2009</verification_date>
  <study_first_submitted>June 26, 2008</study_first_submitted>
  <study_first_submitted_qc>June 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2008</study_first_posted>
  <last_update_submitted>August 30, 2010</last_update_submitted>
  <last_update_submitted_qc>August 30, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 31, 2010</last_update_posted>
  <responsible_party>
    <name_title>Professor Seyed-Moayed Alavian</name_title>
    <organization>Baqiyatallah Research Center for Gastroenterology and Liver Diseases</organization>
  </responsible_party>
  <keyword>Hepatitis C</keyword>
  <keyword>Thalassemia</keyword>
  <keyword>Pegasys</keyword>
  <keyword>Ribavirin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Thalassemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

